Logo image of ABBV

ABBVIE INC (ABBV) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:ABBV - US00287Y1091 - Common Stock

223.32 USD
-0.66 (-0.29%)
Last: 12/12/2025, 8:12:40 PM
222.5 USD
-0.82 (-0.37%)
After Hours: 12/12/2025, 8:12:40 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ABBV. ABBV was compared to 531 industry peers in the Biotechnology industry. While ABBV belongs to the best of the industry regarding profitability, there are concerns on its financial health. ABBV has a decent growth rate and is not valued too expensively. ABBV also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year ABBV was profitable.
In the past year ABBV had a positive cash flow from operations.
ABBV had positive earnings in each of the past 5 years.
Each year in the past 5 years ABBV had a positive operating cash flow.
ABBV Yearly Net Income VS EBIT VS OCF VS FCFABBV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

Looking at the Return On Assets, with a value of 1.75%, ABBV belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
ABBV's Return On Invested Capital of 15.64% is amongst the best of the industry. ABBV outperforms 96.23% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABBV is below the industry average of 18.22%.
The last Return On Invested Capital (15.64%) for ABBV is above the 3 year average (13.67%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ABBV Yearly ROA, ROE, ROICABBV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

ABBV has a better Profit Margin (3.94%) than 89.08% of its industry peers.
ABBV's Profit Margin has declined in the last couple of years.
ABBV's Operating Margin of 33.05% is amongst the best of the industry. ABBV outperforms 96.99% of its industry peers.
In the last couple of years the Operating Margin of ABBV has declined.
ABBV has a better Gross Margin (71.16%) than 81.92% of its industry peers.
ABBV's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
ABBV Yearly Profit, Operating, Gross MarginsABBV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

3

2. Health

2.1 Basic Checks

ABBV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ABBV has about the same amount of shares outstanding.
The number of shares outstanding for ABBV has been increased compared to 5 years ago.
Compared to 1 year ago, ABBV has a worse debt to assets ratio.
ABBV Yearly Shares OutstandingABBV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ABBV Yearly Total Debt VS Total AssetsABBV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

ABBV has an Altman-Z score of 2.42. This is not the best score and indicates that ABBV is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ABBV (2.42) is better than 65.54% of its industry peers.
The Debt to FCF ratio of ABBV is 3.49, which is a good value as it means it would take ABBV, 3.49 years of fcf income to pay off all of its debts.
ABBV has a Debt to FCF ratio of 3.49. This is amongst the best in the industry. ABBV outperforms 92.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.42
ROIC/WACC1.88
WACC8.32%
ABBV Yearly LT Debt VS Equity VS FCFABBV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

A Current Ratio of 0.72 indicates that ABBV may have some problems paying its short term obligations.
ABBV has a worse Current ratio (0.72) than 90.02% of its industry peers.
ABBV has a Quick Ratio of 0.72. This is a bad value and indicates that ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.60, ABBV is doing worse than 90.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
ABBV Yearly Current Assets VS Current LiabilitesABBV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

The earnings per share for ABBV have decreased strongly by -12.09% in the last year.
ABBV shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
The Revenue has been growing slightly by 7.40% in the past year.
The Revenue has been growing by 11.11% on average over the past years. This is quite good.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%

3.2 Future

The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
ABBV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ABBV Yearly Revenue VS EstimatesABBV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B
ABBV Yearly EPS VS EstimatesABBV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 23.63, which indicates a rather expensive current valuation of ABBV.
ABBV's Price/Earnings ratio is rather cheap when compared to the industry. ABBV is cheaper than 93.79% of the companies in the same industry.
When comparing the Price/Earnings ratio of ABBV to the average of the S&P500 Index (26.54), we can say ABBV is valued inline with the index average.
ABBV is valuated correctly with a Price/Forward Earnings ratio of 15.37.
Based on the Price/Forward Earnings ratio, ABBV is valued cheaply inside the industry as 96.23% of the companies are valued more expensively.
ABBV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.78.
Industry RankSector Rank
PE 23.63
Fwd PE 15.37
ABBV Price Earnings VS Forward Price EarningsABBV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

ABBV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ABBV is cheaper than 94.54% of the companies in the same industry.
ABBV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ABBV is cheaper than 95.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.05
EV/EBITDA 16.27
ABBV Per share dataABBV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABBV has a very decent profitability rating, which may justify a higher PE ratio.
ABBV's earnings are expected to grow with 16.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.25
PEG (5Y)9.41
EPS Next 2Y19.81%
EPS Next 3Y16.75%

7

5. Dividend

5.1 Amount

ABBV has a Yearly Dividend Yield of 3.03%.
Compared to an average industry Dividend Yield of 47.55, ABBV pays a better dividend. On top of this ABBV pays more dividend than 99.06% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.27, ABBV pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.03%

5.2 History

On average, the dividend of ABBV grows each year by 7.72%, which is quite nice.
ABBV has paid a dividend for at least 10 years, which is a reliable track record.
ABBV has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)7.72%
Div Incr Years11
Div Non Decr Years11
ABBV Yearly Dividends per shareABBV Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

ABBV pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
The dividend of ABBV is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
ABBV Yearly Income VS Free CF VS DividendABBV Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
ABBV Dividend Payout.ABBV Dividend Payout, showing the Payout Ratio.ABBV Dividend Payout.PayoutRetained Earnings

ABBVIE INC

NYSE:ABBV (12/12/2025, 8:12:40 PM)

After market: 222.5 -0.82 (-0.37%)

223.32

-0.66 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/bmo
Earnings (Next)01-29 2026-01-29/amc
Inst Owners74.96%
Inst Owner Change-0.63%
Ins Owners0.05%
Ins Owner Change-0.57%
Market Cap394.69B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target248.59 (11.32%)
Short Float %1.06%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield 3.03%
Yearly Dividend6.24
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years11
Div Non Decr Years11
Ex-Date01-16 2026-01-16 (1.73)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)2.44%
PT rev (3m)11.92%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)0.63%
EPS NY rev (1m)0.91%
EPS NY rev (3m)-11.53%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.46%
Valuation
Industry RankSector Rank
PE 23.63
Fwd PE 15.37
P/S 6.62
P/FCF 20.05
P/OCF 18.92
P/B N/A
P/tB N/A
EV/EBITDA 16.27
EPS(TTM)9.45
EY4.23%
EPS(NY)14.53
Fwd EY6.5%
FCF(TTM)11.14
FCFY4.99%
OCF(TTM)11.8
OCFY5.29%
SpS33.75
BVpS-1.49
TBVpS-52.38
PEG (NY)3.25
PEG (5Y)9.41
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.42
F-Score7
WACC8.32%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.29%
EBIT Next 3Y15.46%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / ABBV FAQ

Can you provide the ChartMill fundamental rating for ABBVIE INC?

ChartMill assigns a fundamental rating of 5 / 10 to ABBV.


Can you provide the valuation status for ABBVIE INC?

ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (ABBV). This can be considered as Fairly Valued.


Can you provide the profitability details for ABBVIE INC?

ABBVIE INC (ABBV) has a profitability rating of 7 / 10.


What are the PE and PB ratios of ABBVIE INC (ABBV) stock?

The Price/Earnings (PE) ratio for ABBVIE INC (ABBV) is 23.63 and the Price/Book (PB) ratio is -149.39.


Can you provide the financial health for ABBV stock?

The financial health rating of ABBVIE INC (ABBV) is 3 / 10.